drugset / Trial / NCT01268124

Study Evaluating The Safety and Tolerability of HTC-867 in Healthy Japanese Subjects

NCT01268124 ↗

Phase 1 Completed 56 enrolled Wyeth is now a wholly owned subsidiary of Pfizer
RandomizedParallel-groupTriple-blindTreatment

Summary

This is a phase 1, randomized (a process that is used to decide whether you will take study drug or a placebo during the study), inpatient study which will assess the safety and tolerability of HTC-867 in healthy male Japanese subjects.

Timeline

Start
2008-12
Primary completion
2009-04
Completion
2009-04

Drugs

EvaluationDrugModalityDoseRoute
Subject HTC-867 Unknown — Oral

Indications